Osteocalcin and bone-specific alkaline phosphatase in sickle cell haemoglobinopathies.
Osteocalcin or bone gamma-carboxyglutamic acid (gla) protein and Bone-specific alkaline phosphatase (b-AP) total protein levels were evaluated as indicators of bone turnover in twenty patients with sickle cell haemoglobinopathies and in twenty normal healthy individuals. The serum bone-specific alkaline phosphatase total protein level was measured by immunoradiometric (IRMA) method. The concentrations of serum bone-specific alkaline phosphatase total protein were higher in the study group than in the control group [P < 0.05]. The serum osteocalcin (BGP) showed no significant difference with the control healthy subjects. There was no correlation between the serum osteocalcin and serum bone-specific alkaline phosphatase total protein in the patient group. In conclusion, serum bone-specific alkaline phosphatase total protein determined or measured by IRMA can be considered a sensitive marker of bone turnover and could be especially useful as valuable non-invasive biochemical marker for identifying sickle cell patients with bone complications.